View Author
dai: 107991942
scopus: 35237343600
Janssen, H.L.A.
(Harry Janssen)Supervisor (promotor) of 28 dissertations
patient hepatitis study treatment hepatitis b therapy liver level response virus hbsag infection hbeag disease hepatology factor genotype serum effect baseline group peg-ifn hbv dna analysis result control hepatitis b virus lamivudine decline blood signi expression thrombosis follow-up portal rotterdam month peginterferon hepatitis c eur j epidemiol interferon antigen mutation resistance hbeag seroconversion number hbeag-positive survival cirrhosis hbv dna levels seroconversion table combination university hbv-dna gastroenterology hbeag-negative protein rotterdam study hepatitis c virus function signi ficantly model activity dendritic replication hbeag loss trial production population adefovir association t cells department cohort hepatic netherland hepatitis b patients development risk factors
10 Most Recent Publications
|
Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients
(Article)
Spaan, M. Groothuismink, Z.M.A. Koning, L. Roomer, R. Janssen, H.L.A. Knegt, R.J. de Boonstra, A. |
2013-06-01
|
|
Treatment of HCV infection by targeting microRNA
(Article)
Janssen, H.L.A. Reesink, H.W. Persson, R. King, B.D. Kauppinen, S. Levin, A.A. Hodges, M.R. Lawitz, E.J. Zeuzem, S. Rodriguez-Torres, M. Patel, K.V. Meer, A.J.P. van der Patick, A.K. Chen, A.B. Zhou, Y. |
2013-05-13
|
|
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
(Article)
Zoutendijk, R. Reijnders, J.G.P. Berg, T. Hansen, B.E. Sonneveld, M.J. Wedemeyer, H. Janssen, H.L.A. Zoulim, F. Brown, A. Mutimer, D.J. Deterding, K. Hofmann, W.P. Petersen, J. Fasano, M. Buti, M. |
2013-05-01
|
|
Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analogues
(Article)
Zoutendijk, R. Sonneveld, M.J. Reijnders, J.G.P. Vuuren, A.J. van Biesta, P.J. Hansen, B.E. Boonstra, A. Janssen, H.L.A. |
2013-05-01
|
|
Good long-term outcome of Budd-Chiari syndrome with a step-wise management
(Article)
Seijo, S. Plessier, A. Darwish Murad, S. Heller, J. Hadengue, A. Primignani, M. Elias, E. Janssen, H.L.A. Valla, D.C. Garcia-Pagan, J.C. Hoekstra, J.W. Dell'Era, A. Mandair, D. Rifai, K. Trebicka, J. Morard, I. Lasser, L. Abraldes, J.G. |
2013-05-01
|
|
Sustained virological response to treatment in patients with chronic hepatitis C - Reply
(Article)
Meer, A.J.P. van der Hansen, B.E. Janssen, H.L.A. |
2013-04-10
|
|
External Validation of the Fatty Liver Index for Identifying Nonalcoholic Fatty Liver Disease in a Population-based Study
(Article)
Koehler, E.M. Schouten, J.N. Hansen, B.E. Hofman, A. Stricker, B.H.Ch. Janssen, H.L.A. |
2013-04-09
|
|
Response Guided Treatment for Peginterferon in Chronic Hepatitis B
(Article)
Arends, P. Janssen, H.L.A. |
2013-04-08
|
|
Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up
(Article)
Hotho, D.M. Bruijne, J. de Spaan, M. Treitel, M.A. Boonstra, A. Knegt, R.J. de Janssen, H.L.A. Reesink, H.W. |
2013-04-01
|
|
Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up
(Article)
Hotho, D.M. Bruijne, J. de Spaan, M. Treitel, M.A. Boonstra, A. Knegt, R.J. de Janssen, H.L.A. Reesink, H.W. |
2013-04-01
|
